SUPPLEMENTARY DATA

Figure 1 of the supplementary data

Association between baseline United Kingdom National Amyloid Centre stages* and long-term survival (panel A) and long-term survival free of heart failure hospitalization (panel B) in patients with cardiac amyloidosis: Kaplan-Meier analysis.

A



B



*Stage I = NT-proBNP≤3000 pg/mL and glomerular filtration rate ≥45 mL/min.

Stage III = NT-proBNP>3000 pg/mL and glomerular filtration rate <45 mL/min.

Stage II = Patients not classified as stage I or stage III.

As per Gillmore J, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018; 39: 2799-2806. (Reference 15 of the main paper).

Table 1 of the supplementary data.

Statistical associations between baseline variables selected as potential confounders and all-cause mortality: univariate and multivariate Cox regression analyses.

Models and variables	Univariate	Multivariate
Model 1 (clinical variables)		
Age, y	1.09 (1.04-1.14)	1.11 (1.06-1.16)
Male sex	1.33 (0.75-2.35)	2.16 (1.18-3.97)
Transthyretin type vs other types	0.69 (0.33-1.46)	0.22 (0.09-0.56)
NYHA class	2.70 (1.65-4.41)	1.80 (1.04-3.12)
Physical signs of congestion	2.85 (1.62-5.03)	1.58 (0.83-3.03)
Atrial fibrillation or flutter	1.06 (0.65-1.73)	0.73 (0.43-1.23)
Model 2 (laboratory variables)		
NTproBNP (per 100 ng/mL)	1.007 (1.004-1.010)	1.009 (1.003-1.014)
Glomerular filtration rate, mL/min	0.992 (0.980-1.004)	1.013 (0.994-1.033)
Potassium, mEq/L	0.88 (0.52-1.52)	1.44 (0.80-2.56)
Uric acid, mg/dL	1.11 (1.00-1.23)	1.13 (1.01-1.27)
Urea, mg/dL	1.004 (0.998-1.009)	0.999 (0.990-1.008)
Gamma glutamyl transpherase, UI/mL	1.001 (0.999-1.002)	0.998 (0.996-1.001)
Alkaline phosphatase, UI/mL	1.002 (1.000-1.004)	1.002 (0.999-1.004)
Model 3 (echocardiographic variables)		
Left ventricular ejection fraction, %	0.98 (0.96-1.01)	1.01 (0.98-1.03)
Maximum left ventricular wall thickness, mm	1.07 (1.01-1.14)	1.07 (1.01-1.15)
Moderate or severe mitral regurgitation	1.51 (0.86-2.66)	1.26 (0.67-2.36)
Moderate or severe tricuspid regurgitation	1.48 (0.49-2.86)	0.85 (0.47-1.53)
Model 4 (treatment variables)		

Loop diuretic	1.77 (0.92-3.41)	1.40 (0.66-2.95)
Mineralocorticoid receptor antagonist	1.49 (0.89-2.47)	1.06 (0.61-1.84)
Beta-blocker	0.84 (0.52-1.86)	0.67 (0.39-1.17)
Anticoagulation	0.89 (0.55-1.54)	0.60 (0.34-1.05)
Model 5 (UK NAC staging system)		
UK NAC stage II vs I	4.14 (2.16-7.95)	3.01 (1.51-6.02)
UK NAC stage III vs II	2.90 (1.41-5.99)	2.05 (0.96-4.40)

NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; UK NAC, United Kingdom National Amyloid Center.

Table 2 of the supplementary data.

Statistical associations between baseline variables selected as potential confounders and the combined endpoint of all-cause mortality or heart failure hospitalization: univariate and multivariate Cox regression analyses.

	Univariate	Multivariate
Model 1 (clinical variables)		
Age, y	1.01 (0.98-1.03)	1.03 (0.99-1.06)
Male sex	1.20 (0.77-1.87)	1.97 (1.22-3.16)
Transthyretin type vs other types	0.53 (0.31-0.91)	0.38 (0.19-0.76)
NYHA class	2.87 (1.95-4.21)	2.03 (1.33-3.09)
Physical signs of congestion	2.95 (1.90-4.57)	2.00 (1.23-3.36)
Atrial fibrillation or flutter	1.05 (0.72-1.54)	0.62 (0.41-0.95)
Model 2 (laboratory variables)		
NTproBNP (per 100 ng/mL)	1.005 (1.002-1.008)	1.005 (1.001-1.009)
Glomerular filtration rate, mL/min	0.993 (0.984-1.003)	1.011 (0.996-1.026)
Potassium, mEq/L	0.73 (0.48-1.12)	1.02 (0.66-1.59)
Uric acid, mg/dL	1.18 (1.09-1.27)	1.20 (1.09-1.32)
Urea, mg/dL	1.004 (1.000-1.008)	0.999 (0.992-1.006)
Gamma glutamyl transpherase, UI/mL	1.001 (1.000-1.003)	1.000 (0.998-1.002)
Alkaline phosphatase, UI/mL	1.001 (1.000-1.003)	1.001 (0.999-1.003)
Model 3 (echocardiographic variables)		
Left ventricular ejection fraction, %	0.97 (0.96-0.99)	0.99 (0.97-1.01)
Maximum left ventricular wall thickness, mm	1.05 (0.99-1.10)	1.04 (0.98-1.10)
Moderate or severe mitral regurgitation	1.56 (1.00-2.42)	1.17 (0.73-1.90)
Moderate or severe tricuspid regurgitation	1.39 (0.92-2.09)	0.81 (0.51-1.28)
Model 4 (treatment variables)		
Loop diuretic	1.96 (1.15-3.34)	1.53 (0.85-2.76)
Mineralocorticoid receptor antagonist	1.62 (1.09-2.41)	1.22 (0.79-1.88)
Beta-blocker	0.90 (0.61-1.32)	0.70 (0.46-1.08)

Anticoagulation	0.95 (0.64-1.39)	0.75 (0.49-1.14)
Model 5 (UK NAC staging system)		
UK NAC stage II vs I	3.90 (2.37-6.42)	3.06 (1.81-5.17)
UK NAC stage III vs I	3.32 (1.92-5.75)	2.45 (1.37-4.38)

NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; UK NAC, United Kingdom National Amyloid Center.